Banco Santander S.A. grew its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,914 shares of the biopharmaceutical company’s stock after acquiring an additional 514 shares during the quarter. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $3,864,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in REGN. AE Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $219,000. Janney Montgomery Scott LLC boosted its position in Regeneron Pharmaceuticals by 136.9% during the 4th quarter. Janney Montgomery Scott LLC now owns 6,901 shares of the biopharmaceutical company’s stock worth $2,591,000 after acquiring an additional 3,988 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,128 shares of the biopharmaceutical company’s stock worth $7,558,000 after acquiring an additional 577 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $267,000. Finally, Exchange Traded Concepts LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $88,000. 66.58% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on the company. Cowen upped their price objective on Regeneron Pharmaceuticals from $386.00 to $495.00 and gave the stock a “market perform” rating in a research note on Friday, February 28th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $466.00 to $525.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 6th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $500.00 price objective on the stock in a research note on Wednesday, February 26th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They set a “market perform” rating and a $455.00 price objective on the stock. Finally, Oppenheimer upped their price objective on Regeneron Pharmaceuticals from $525.00 to $625.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $515.26.
In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, March 30th. The stock was sold at an average price of $466.69, for a total transaction of $46,669.00. Following the sale, the director now directly owns 29,141 shares of the company’s stock, valued at approximately $13,599,813.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director George L. Sing sold 850 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $575.00, for a total value of $488,750.00. Following the sale, the director now directly owns 120,415 shares in the company, valued at $69,238,625. The disclosure for this sale can be found here. Over the last three months, insiders have sold 196,397 shares of company stock worth $109,206,506. 11.84% of the stock is currently owned by insiders.
NASDAQ REGN traded up $8.93 on Friday, reaching $569.91. The stock had a trading volume of 645,971 shares, compared to its average volume of 1,013,818. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.21 and a quick ratio of 3.49. The firm has a fifty day moving average of $541.71 and a two-hundred day moving average of $427.59. Regeneron Pharmaceuticals Inc has a 1-year low of $271.37 and a 1-year high of $583.54. The company has a market cap of $61.72 billion, a P/E ratio of 28.64, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $6.60 EPS for the quarter, beating analysts’ consensus estimates of $6.13 by $0.47. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The firm had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.81 billion. During the same period in the prior year, the firm posted $4.45 EPS. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals Inc will post 23.84 EPS for the current fiscal year.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Understanding the different types of bonds
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.